Story perspectives
UK's Medicine Funding Stagnates, Harming Innovation and Investment
10/9/2025
1 of 1
Story summary
- The National Institute for Health and Care Excellence (NICE) funding threshold for new medicines hasn't changed in over 20 years, reducing real-terms value by 47% since 1999.
- This stagnation harms the UK’s global competitiveness in life sciences and deters investment in innovative treatments.
- Experts say the threshold is among the lowest among countries with explicit funding levels.
